Catalent Inc Revenue Growth Rates (CTLT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Catalent Inc   (NYSE: CTLT)
 

CTLT's Revenue Growth by Quarter and Year

Catalent Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CTLT Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 1,023.00
FY 1,023.00

CTLTs Annual Revenue
Catalent Inc 's Revenue in the fiscal year 2024 $ 4,381.00 millions
Catalent Inc 's Revenue in the fiscal year 2023 $ 4,263.00 millions
Catalent Inc 's Revenue in the fiscal year 2022 $ 4,802.00 millions
Catalent Inc 's Revenue in the fiscal year 2021 $ 3,998.00 millions
Catalent Inc 's Revenue in the fiscal year 2020 $ 3,094.30 millions




CTLT Revenue first quarter 2025 Y/Y Growth Comment
Catalent Inc reported Revenue growth of 4.18% year on year in the first quarter 2025, to $ 1,023.00 millions, this is lower than Catalent Inc 's recent average Revenue increase of 10.83%.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 129 other companies have achieved higher Revenue growth. While Catalent Inc ' s Revenue increase of 4.18% ranks overall at the positon no. 1838 in the first quarter 2025.


CTLT Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter June - 23.32 % -18.03 % 8.32 %
3rd Quarter March - 3.57 % -18.54 % 20.86 %
2nd Quarter December - -10.88 % -5.59 % 33.62 %
1st Quarter September 4.18 % -3.91 % -0.29 % 21.2 %
FY   - 2.77 % -11.22 % -

Financial Statements
Catalent Inc 's first quarter 2025 Revenue $ 1,023.00 millions CTLT's Income Statement
Catalent Inc 's first quarter 2024 Revenue $ 982.00 millions Quarterly CTLT's Income Statement


CTLT Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter June - 21.14 % 1.74 % 1.1 %
3rd Quarter March - 4.88 % -9.75 % 4.6 %
2nd Quarter December - 4.28 % 12.43 % 18.73 %
1st Quarter September -21.37 % -6.92 % -20.59 % -13.74 %
FY (Year on Year)   - 2.77 % -11.22 % -


Back to CTLT Growth rate Comparisons >> Back to CTLT Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #345
Overall #1838

Revenue Y/Y Growth Statistics
High Average Low
38.48 % 10.83 % -27.28 %
(Mar 31 2021)   (Jun 30 2023)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #130
Healthcare Sector #345
Overall #1838
Revenue Y/Y Growth Statistics
High Average Low
38.48 % 10.83 % -27.28 %
(Mar 31 2021)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Catalent Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
24.59 % 2.71 % -29.55 %
(Jun 30 2020)  


CTLT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Catalent Inc disclosed fall in Revenue from the fourth quarter by -21.37% to $ 1,023.00 millions, from $ 1,301.00 millions achived in the previous reporting period.

But that's not important problem, as Catalent Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 195 other companies have achieved higher Revenue quarter on quarter growth. While Catalent Inc 's Revenue growth quarter on quarter, overall rank is 3600.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #196
Healthcare Sector #542
Overall #3600
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #196
Healthcare Sector #542
Overall #3600
Revenue Q/Q Growth Statistics
High Average Low
24.59 % 2.71 % -29.55 %
(Jun 30 2020)  


CTLT's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Catalent Inc disclosed fall in Revenue from the fourth quarter by -21.37% to $ 1,023.00 millions, from $ 1,301.00 millions achived in the previous reporting period.

But that's not important problem, as Catalent Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 195 other companies have achieved higher Revenue quarter on quarter growth. While Catalent Inc 's Revenue growth quarter on quarter, overall rank is 3600.


Catalent Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 4,422.00 $ 4,381.00 $ 4,135.00 $ 4,098.00 $ 4,223.00
Y / Y Revenue Growth (TTM) 4.71 % 2.77 % -8.01 % -13.38 % -12 %
Year on Year Revenue Growth Overall Ranking # 2921 # 2302 # 878 # 137 # 1066
Seqeuential Revenue Change (TTM) 0.94 % 5.95 % 0.9 % -2.96 % -0.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 2349 # 2119 # 1983 # 446 # 2752


Cumulative Revenue growth Comment
Although Catalent Inc 's Annual Revenue growth year on year were below company's average 7.86% , Revenue announced in the Sep 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.71% year on year, from 2.77% in Jun 30 2024.

In the Healthcare sector 423 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2302 to 2921.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 424
Overall # 2921

Revenue TTM Y/Y Growth Statistics
High Average Low
31.39 %
 7.86 %
-68.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 392
S&P 500 # 2349
Cumulative Revenue growth Comment
Although Catalent Inc 's Annual Revenue growth year on year were below company's average 7.86% , Revenue announced in the Sep 30 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.71% year on year, from 2.77% in Jun 30 2024.

In the Healthcare sector 423 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2302 to 2921.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 424
Overall # 2921

Revenue TTM Y/Y Growth Statistics
High Average Low
31.39 %
7.86 %
-68.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 141
Sector # 392
S&P 500 # 2349




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CTLT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Addus Homecare Corp7.22%$ 7.220 millions
Ati Physical Therapy Inc 7.06%$ 7.062 millions
Fennec Pharmaceuticals Inc 7.05%$ 7.045 millions
Gilead Sciences Inc 7.01%$ 7.006 millions
Mountain Crest Acquisition Corp V6.94%$ 6.938 millions
Becton Dickinson And Company6.88%$ 6.880 millions
Vaso Corporation6.72%$ 6.720 millions
Merus N v 6.70%$ 6.698 millions
Orthofix Medical Inc 6.69%$ 6.688 millions
Idexx Laboratories Inc6.56%$ 6.564 millions
Icu Medical Inc6.50%$ 6.499 millions
Aveanna Healthcare Holdings Inc 6.49%$ 6.488 millions
Integer Holdings Corporation6.43%$ 6.430 millions
Reshape Lifesciences Inc6.36%$ 6.357 millions
Vyne Therapeutics Inc 6.14%$ 6.140 millions
Organogenesis Holdings Inc 6.12%$ 6.124 millions
Amphastar Pharmaceuticals Inc 5.90%$ 5.903 millions
Carlisle Companies Incorporated5.86%$ 5.858 millions
Inogen Inc 5.80%$ 5.796 millions
Select Medical Holdings Corp5.73%$ 5.735 millions
Amedisys Inc5.65%$ 5.651 millions
Avalo Therapeutics Inc 5.51%$ 5.508 millions
Revance Therapeutics Inc 5.47%$ 5.465 millions
Masimo Corp5.30%$ 5.305 millions
Royalty Pharma Plc5.29%$ 5.291 millions
Ardent Health Inc 5.23%$ 5.233 millions
Viskase Holdings inc 5.14%$ 5.145 millions
Privia Health Group Inc 4.95%$ 4.946 millions
Tactile Systems Technology Inc 4.94%$ 4.942 millions
Abbott Laboratories4.85%$ 4.851 millions


About Catalent Inc Revenue Growth Rates (CTLT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Catalent Inc (CIK 1596783).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001596783-24-000120
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Catalent Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.